Titre : 2-Cyano-acrylate d'isobutyle

2-Cyano-acrylate d'isobutyle : Questions médicales fréquentes

Termes MeSH sélectionnés :

Combined Modality Therapy

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment le Bucrylate est-il utilisé en diagnostic ?

Il n'est pas utilisé pour le diagnostic, mais pour la fermeture des plaies.
Adhésifs Chirurgie Plaies
#2

Quels tests sont nécessaires avant d'utiliser le Bucrylate ?

Aucun test spécifique n'est requis, mais l'historique allergique doit être vérifié.
Allergies Antécédents médicaux Chirurgie

Symptômes 2

#1

Quels symptômes peuvent survenir après l'application de Bucrylate ?

Des rougeurs, démangeaisons ou gonflements peuvent apparaître au site d'application.
Réaction cutanée Symptômes Dermatologie
#2

Le Bucrylate peut-il provoquer des douleurs ?

Des douleurs légères peuvent survenir, mais elles sont généralement temporaires.
Douleur Chirurgie Effets indésirables

Prévention 2

#1

Comment prévenir les réactions allergiques au Bucrylate ?

Évaluer l'historique allergique et effectuer un test cutané si nécessaire.
Allergies Prévention Chirurgie
#2

Quelles précautions doivent être prises lors de l'utilisation du Bucrylate ?

Éviter le contact avec les yeux et les muqueuses, et utiliser dans un environnement stérile.
Précautions Chirurgie Stérilité

Traitements 2

#1

Le Bucrylate est-il utilisé pour traiter des infections ?

Non, il est utilisé pour la fermeture des plaies, pas pour traiter les infections.
Infections Chirurgie Plaies
#2

Comment le Bucrylate favorise-t-il la cicatrisation ?

Il forme une barrière protectrice qui aide à maintenir l'humidité et à réduire l'infection.
Cicatrisation Adhésifs Chirurgie

Complications 2

#1

Quelles complications peuvent survenir avec le Bucrylate ?

Des infections, des réactions allergiques ou des cicatrices anormales peuvent survenir.
Complications Infections Cicatrices
#2

Le Bucrylate peut-il causer des réactions systémiques ?

Des réactions systémiques sont rares, mais possibles en cas d'allergie sévère.
Réactions systémiques Allergies Chirurgie

Facteurs de risque 2

#1

Qui est à risque d'allergie au Bucrylate ?

Les personnes ayant des antécédents d'allergies aux adhésifs ou aux cyanoacrylates.
Facteurs de risque Allergies Chirurgie
#2

Les enfants peuvent-ils utiliser le Bucrylate ?

Oui, mais avec prudence et sous supervision médicale en raison de leur peau sensible.
Enfants Chirurgie Adhésifs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "2-Cyano-acrylate d'isobutyle : Questions médicales les plus fréquentes", "headline": "2-Cyano-acrylate d'isobutyle : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les 2-Cyano-acrylate d'isobutyle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-15", "dateModified": "2025-04-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "2-Cyano-acrylate d'isobutyle" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Enbucrilate", "url": "https://questionsmedicales.fr/mesh/D004659", "about": { "@type": "MedicalCondition", "name": "Enbucrilate", "code": { "@type": "MedicalCode", "code": "D004659", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.051.919.367.341" } } }, "about": { "@type": "MedicalCondition", "name": "2-Cyano-acrylate d'isobutyle", "alternateName": "Bucrylate", "code": { "@type": "MedicalCode", "code": "D002015", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Michael Schultheiß", "url": "https://questionsmedicales.fr/author/Michael%20Schulthei%C3%9F", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany." } }, { "@type": "Person", "name": "Max Giesler", "url": "https://questionsmedicales.fr/author/Max%20Giesler", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany." } }, { "@type": "Person", "name": "Lars Maruschke", "url": "https://questionsmedicales.fr/author/Lars%20Maruschke", "affiliation": { "@type": "Organization", "name": "Department of Radiology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany." } }, { "@type": "Person", "name": "Arthur Schmidt", "url": "https://questionsmedicales.fr/author/Arthur%20Schmidt", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany." } }, { "@type": "Person", "name": "Lukas Sturm", "url": "https://questionsmedicales.fr/author/Lukas%20Sturm", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.", "datePublished": "2023-08-06", "url": "https://questionsmedicales.fr/article/37586927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clcc.2023.08.002" } }, { "@type": "ScholarlyArticle", "name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36351568", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14724" } }, { "@type": "ScholarlyArticle", "name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.", "datePublished": "2022-07-17", "url": "https://questionsmedicales.fr/article/35963771", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clml.2022.07.005" } }, { "@type": "ScholarlyArticle", "name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36102865", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DCR.0000000000002600" } }, { "@type": "ScholarlyArticle", "name": "Radiation therapy modalities for keloid management: A critical review.", "datePublished": "2022-05-06", "url": "https://questionsmedicales.fr/article/35817711", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bjps.2022.04.099" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Produits manufacturés", "item": "https://questionsmedicales.fr/mesh/D008420" }, { "@type": "ListItem", "position": 4, "name": "Matériaux biomédicaux et dentaires", "item": "https://questionsmedicales.fr/mesh/D001697" }, { "@type": "ListItem", "position": 5, "name": "Adhésifs tissulaires", "item": "https://questionsmedicales.fr/mesh/D014014" }, { "@type": "ListItem", "position": 6, "name": "Cyanoacrylates", "item": "https://questionsmedicales.fr/mesh/D003487" }, { "@type": "ListItem", "position": 7, "name": "Enbucrilate", "item": "https://questionsmedicales.fr/mesh/D004659" }, { "@type": "ListItem", "position": 8, "name": "2-Cyano-acrylate d'isobutyle", "item": "https://questionsmedicales.fr/mesh/D002015" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : 2-Cyano-acrylate d'isobutyle - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur 2-Cyano-acrylate d'isobutyle", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur 2-Cyano-acrylate d'isobutyle", "description": "Comment le Bucrylate est-il utilisé en diagnostic ?\nQuels tests sont nécessaires avant d'utiliser le Bucrylate ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur 2-Cyano-acrylate d'isobutyle", "description": "Quels symptômes peuvent survenir après l'application de Bucrylate ?\nLe Bucrylate peut-il provoquer des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur 2-Cyano-acrylate d'isobutyle", "description": "Comment prévenir les réactions allergiques au Bucrylate ?\nQuelles précautions doivent être prises lors de l'utilisation du Bucrylate ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur 2-Cyano-acrylate d'isobutyle", "description": "Le Bucrylate est-il utilisé pour traiter des infections ?\nComment le Bucrylate favorise-t-il la cicatrisation ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur 2-Cyano-acrylate d'isobutyle", "description": "Quelles complications peuvent survenir avec le Bucrylate ?\nLe Bucrylate peut-il causer des réactions systémiques ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur 2-Cyano-acrylate d'isobutyle", "description": "Qui est à risque d'allergie au Bucrylate ?\nLes enfants peuvent-ils utiliser le Bucrylate ?", "url": "https://questionsmedicales.fr/mesh/D002015?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le Bucrylate est-il utilisé en diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il n'est pas utilisé pour le diagnostic, mais pour la fermeture des plaies." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant d'utiliser le Bucrylate ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Aucun test spécifique n'est requis, mais l'historique allergique doit être vérifié." } }, { "@type": "Question", "name": "Quels symptômes peuvent survenir après l'application de Bucrylate ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des rougeurs, démangeaisons ou gonflements peuvent apparaître au site d'application." } }, { "@type": "Question", "name": "Le Bucrylate peut-il provoquer des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs légères peuvent survenir, mais elles sont généralement temporaires." } }, { "@type": "Question", "name": "Comment prévenir les réactions allergiques au Bucrylate ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Évaluer l'historique allergique et effectuer un test cutané si nécessaire." } }, { "@type": "Question", "name": "Quelles précautions doivent être prises lors de l'utilisation du Bucrylate ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le contact avec les yeux et les muqueuses, et utiliser dans un environnement stérile." } }, { "@type": "Question", "name": "Le Bucrylate est-il utilisé pour traiter des infections ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, il est utilisé pour la fermeture des plaies, pas pour traiter les infections." } }, { "@type": "Question", "name": "Comment le Bucrylate favorise-t-il la cicatrisation ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il forme une barrière protectrice qui aide à maintenir l'humidité et à réduire l'infection." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le Bucrylate ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des infections, des réactions allergiques ou des cicatrices anormales peuvent survenir." } }, { "@type": "Question", "name": "Le Bucrylate peut-il causer des réactions systémiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions systémiques sont rares, mais possibles en cas d'allergie sévère." } }, { "@type": "Question", "name": "Qui est à risque d'allergie au Bucrylate ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents d'allergies aux adhésifs ou aux cyanoacrylates." } }, { "@type": "Question", "name": "Les enfants peuvent-ils utiliser le Bucrylate ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, mais avec prudence et sous supervision médicale en raison de leur peau sensible." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 09/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Michael Schultheiß

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Max Giesler

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Lars Maruschke

1 publication dans cette catégorie

Affiliations :
  • Department of Radiology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Arthur Schmidt

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Lukas Sturm

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Robert Thimme

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Martin Rössle

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. Martin-Roessle@t-online.de.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Dominik Bettinger

1 publication dans cette catégorie

Affiliations :
  • Department of Gastroenterology, University Hospital of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Publications dans "2-Cyano-acrylate d'isobutyle" :

Sources (10000 au total)

Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.

We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC).... This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s... Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ... Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...

Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.

The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria... This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe... We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi... For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....

Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.

There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer.... This study aimed to evaluate long-term changes in patients treated with combined modality.... This was a retrospective study of prospectively collected patient-reported outcome surveys.... This study was conducted at a single institution.... There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey.... This study included patient-reported outcomes reflecting bowel, sexual, and urinary function.... Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9... This was a single-institution study and only patients who answered the questionnaire were included in the study.... A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was... ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...

Radiation therapy modalities for keloid management: A critical review.

To provide a critical overview of current radiation modalities for keloid management.... Despite multimodal therapies, keloids that can develop following injury are poorly controlled. A number of studies have suggested that post-excisional radiation therapy can reduce rates of keloid recu... Electron beam radiation and high-dose rate brachytherapy are the two most commonly used modalities for adjuvant radiotherapeutic management of keloids and can provide effective keloid control but may ... While radiation therapy is a promising modality for treating keloids, more studies of a prospective, randomized nature are needed to standardize its utility....

PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).

Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder... Patients underwent baseline... In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien... The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder... NCT00002014-000860-16....

Neurotoxins and Combination Therapies.

Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often... To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans.... This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ... Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme... Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...

Combined therapy with CD4

Monotherapy with autologous expanded CD4... We conducted a three-arms clinical trial to explore the efficacy and safety of the combined treatment with Tregs and rituximab in paediatric patients with T1DM. The patients were allocated to three gr... At month 24, as compared with the control, both treatment groups remained superior in the area under the curve of C-peptide mixed meal tolerance test, whereas in the analysis of all visits only the co... Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission....

Combination therapies for cancer: challenges and opportunities.

Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti... Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel... Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...